• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zenas BioPharma Stock In Focus After Wider Quarterly Loss

    Simply Wall St·11/06/2026 04:56:22
    Listen to the news
    • Zenas BioPharma reported third quarter 2026 revenue of US$10 million, with a net loss of US$108.92 million and basic and diluted loss per share from continuing operations of US$1.65, compared with a smaller loss in the same period in 2025.
    • Across the first nine months of 2026, the business generated US$11 million of revenue while reporting a net loss of US$301.37 million and a higher loss per share than a year earlier, which reflects the impact that ongoing spending has on the income statement ahead of any potential product launches.
    • We will now look at how Zenas BioPharma’s wider third quarter loss could influence the investment narrative around its cash burn.

    Compare Zenas BioPharma's current profile with a curated set of beaten-down yet fundamentally sound healthcare names in our 32 resilient stocks with low risk scores to see how other balance sheet focused plays stack up.

    Zenas BioPharma Investment Narrative Recap

    To own Zenas BioPharma, you need to believe its immunology pipeline, led by obexelimab, can eventually justify years of heavy losses and future commercialization efforts. The latest quarter reinforced that trade off. Revenue reached US$10 million, but the net loss of US$108.92 million and higher loss per share underline how dependent the story is on future product uptake rather than current income.

    The near term hinge point still sits around regulatory progress and launch readiness for obexelimab in IgG4 related disease, with the accepted Biologics License Application and upcoming EMA filing as key milestones. The biggest risk remains cash burn. Nine month losses of US$301.37 million highlight how prolonged timelines or slower than expected adoption could pressure funding needs and shareholder dilution.

    The most relevant reference point for this earnings update is the prior context around obexelimab's U.S. filing in IgG4 RD, which already has a May 27, 2027 PDUFA date. That application frames the whole income statement. Current spending on R&D and pre commercial work feeds directly into the wider loss profile seen in the latest quarter.

    Everything links back to whether Zenas BioPharma can convert that regulatory track into real world use among the roughly 25,000 diagnosed and managed U.S. IgG4 RD patients management has discussed. Execution on the planned field force of 45 representatives, the HUB model, and the specialty pharmacy footprint will influence how efficiently any approval can translate into revenue that starts to offset the level of losses now being reported.

    Zenas BioPharma's narrative references analyst assumptions that revenue could reach US$246.7 million and earnings could reach US$39.4 million by 2029. This implies a very large yearly revenue growth rate of 527.1% and an earnings move of about US$523.8 million from current earnings of a US$484.4 million loss today.

    Uncover why Zenas BioPharma's fair value indicates an 85% potential upside to its current price, which could narrow quickly.

    NasdaqGS:ZBIO 1-Year Stock Price Chart
    NasdaqGS:ZBIO 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist in the Zenas BioPharma story is how optimistic analysts were about long term earnings power before this earnings release. The most upbeat forecasts pointed to revenue of about US$414.5 million and earnings of US$71.5 million by 2029. Those expectations reflect a much more optimistic narrative that may shift after these results.

    Explore 2 other Zenas BioPharma fair value estimates, including one that suggests as much as 128% upside from the current price.

    Form Your Own Verdict

    Don't just follow the ticker, dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Zenas BioPharma?

    Once you have formed a view on Zenas BioPharma, it can help to compare that thesis with other opportunities that fit different risk and income profiles. The Simply Wall St Screener gives you a structured way to do that, using filters that focus on quality, resilience, and potential mispricing.